We further suggest that preclinical studies of fatty liver diseases may yield information whether the course of fatty liver disease is attenuated by pharmaceuticals targeting not only the various components of the three complement pathways but also the C1q-ApoE complex itself and whether liver fibrosis, its development into liver cirrhosis and HCC may be halted by such treatment regimens. The gene discussed is APOE; the disease is Hepatic fibrosis.